Foghorn Therapeutics Inc.

NasdaqGM:FHTX Aktierapport

Börsvärde: US$349.3m

Foghorn Therapeutics Framtida tillväxt

Future kriterier kontrolleras 2/6

Foghorn Therapeutics förväntas öka vinsten och intäkterna med 30.5% och 35.9% per år respektive medan EPS förväntas växa med 38.9% per år.

Viktig information

30.5%

Tillväxttakt i vinsten

38.93%

Tillväxttakt för EPS

Biotechs vinsttillväxt25.1%
Intäkternas tillväxttakt35.9%
Framtida avkastning på eget kapitaln/a
Bevakning av analytiker

Good

Senast uppdaterad16 Jun 2026

Senaste uppdateringarna om framtida tillväxt

Analysartikel • May 11

Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report

Shareholders might have noticed that Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) filed its quarterly result this time...
Analysartikel • Nov 07

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) just released its third-quarter report and things are looking bullish...
Analysartikel • May 09

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders are probably feeling a little disappointed, since its shares...

Recent updates

Analysartikel • May 11

Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report

Shareholders might have noticed that Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) filed its quarterly result this time...
Analysartikel • Dec 23

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders would be excited to see that the share price has had a great...
Analysartikel • Dec 19

Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysartikel • Sep 07

We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • Jul 10

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares May Have Run Too Fast Too Soon

With a price-to-sales (or "P/S") ratio of 13.1x Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) may be sending very bearish...
Analysartikel • Apr 09

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

The Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) share price has fared very poorly over the last month, falling by a...
Seeking Alpha • Mar 26

Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients

Summary Foghorn Therapeutics remains a "hold" due to ongoing development of FHD-909 for SMARCA4 solid tumors, with key data expected by late 2025/early 2026. Partnership with Eli Lilly strengthens FHD-909's prospects, focusing on NSCLC patients with SMARCA4 mutation & other programs; Upfront $380 million payment and up to $1.3 billion milestone payments. Preclinical results of FHD-909 combined with KEYTRUDA and KRAS inhibitors will be presented at AACR in April 2025, offering an early catalyst. The global non-small lung carcinoma market is predicted to reach $21.51 billion by the end of 2033; Up to 10% of NSCLC solid tumors express SMARCA4 mutation. Read the full article on Seeking Alpha
Analysartikel • Feb 23

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 29% But Growth Is Lacking

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders are no doubt pleased to see that the share price has bounced 29...
Analysartikel • Feb 08

Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysartikel • Jan 01

More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 41%

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders that were waiting for something to happen have been dealt a blow...
Analysartikel • Nov 07

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) just released its third-quarter report and things are looking bullish...
Analysartikel • Oct 22

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk

The Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) share price has softened a substantial 28% over the previous 30 days...
Analysartikel • Sep 01

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

The Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) share price has done very well over the last month, posting an excellent...
Analysartikel • Jul 17

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shares have had a really impressive month, gaining 27% after a shaky period...
Analysartikel • May 09

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders are probably feeling a little disappointed, since its shares...
Analysartikel • Apr 12

Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysartikel • Feb 22

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders would be excited to see that the share price has had a great...
Analysartikel • Dec 13

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Those holding Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shares would be relieved that the share price has rebounded 33...
Analysartikel • Nov 07

Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Shareholders in Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) may be thrilled to learn that the analysts have just...
Analysartikel • Jun 14

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 10

Foghorn Therapeutics: Selling For Less Than Cash Value

Summary Today, we put Foghorn Therapeutics in the spotlight for the first time. The company is developing several early stage drug candidates, and the stock trades currently for less than the net cash on the balance sheet. An investment analysis follows in the paragraphs below. One of the advantages of being disorganized is that one is always having surprising discoveries.”― A.A. Milne Today, we take our first look at Foghorn Therapeutics Inc. (FHTX). This small biotech concern came public in 2020 and now finds itself in Busted IPO territory. In a testament to how cruel 2022 has been to small biotech concerns, Foghorn is one of myriad biotech stocks that currently trade for less than the net cash on its balance sheet. The company does have a bevy of early stage drug candidates currently in development. An analysis follows below. Seeking Alpha Company Overview: Foghorn Therapeutics is based just outside of Boston in Cambridge, MA. This clinical-stage biopharmaceutical company is focused on developing medicines targeting genetically determined dependencies within the chromatin regulatory system. The company develops drug candidates utilizing its proprietary Gene Traffic Control platform that identifies and validates potential drug targets within the system. The stock currently trades for just over $8.00 a share and sports an approximate market capitalization of $330 million. September Company Presentation The company is utilizing enzyme inhibition and protein degradation approaches to potentially treat cancers, including uveal melanoma and synovial sarcoma. Foghorn is targeting one of the ways cells regulate gene expression by using chromatin in the so-called chromatin gene regulatory system. It has dubbed this approach "Gene Traffic Control." Foghorn has developmental partnership deals with drug giants Merck (MRK) and Eli Lilly (LLY). The partnership with Loxo Oncology, a division of Lilly, brought in a $380 million upfront payment. The one with Merck consisted of a $15 million upfront payment as well as a potential $410 million in various milestone payouts. September Company Presentation As you can see above, most of the candidates within Foghorn's pipeline are early staged and partnered with larger drug players. One of its wholly owned candidates is FHD-286. This compound is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM and is targeting multiple indications. September Company Presentation FHD-286 is in Phase I development. Unfortunately, in late August the FDA slapped a full clinical hold on the Foghorn's phase 1 dose escalation study of FHD-286 in patients with relapsed and/or refractory acute myelogenous leukemia ((AML)) and myelodysplastic syndrome [MDS]. This follows a partial hold issued in May and comes as a result of additional suspected cases of fatal differentiation syndrome. The FDA has questions, and this will require further analysis before the hold could be potentially lifted. A Phase 1 dose escalation study of FHD-286 in metastatic uveal melanoma (mUM) will continue as plan. Initial results from this trial should be out in the first half of 2023. September Company Presentation The company is currently enrolling patients in a Phase 1 clinical study evaluating FHD-609 in synovial sarcoma is also due out in 2023. FHD-609 is a potent and selective heterobifunctional protein degrader of BRD9. September Company Presentation All the partnered candidates in Foghorn's pipeline are in even earlier stages of development. The company did receive $4.5 million worth of collaboration revenue via its partnership with Loxo Oncology in the second quarter and will receive a $5 million milestone payout from Merck in the third quarter. Analyst Commentary & Balance Sheet: So far in 2022, Wedbush, Goldman Sachs ($21 price target) and H.C. Wainwright ($25 price target) have reissued Buy ratings on Foghorn Therapeutics, while Morgan Stanley ($15 price target) has maintained a Hold rating on the stock.
Seeking Alpha • Aug 23

Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286

The U.S. Food and Drug Administration (FDA) placed a full clinical hold on Foghorn Therapeutics' (NASDAQ:FHTX) phase 1 dose escalation study of FHD-286 in patients with relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after additional suspected cases of fatal differentiation syndrome. The FDA had placed partial hold on the study in May following the report of a death due to a potential differentiation syndrome. The company said in an Aug. 23 press release that the full clinical hold in the study was due to the observation, in the data submitted in response to the partial hold, of additional suspected cases of fatal differentiation syndrome believed to be linked with FHD-286. Foghorn added that Differentiation syndrome is linked with AML/MDS therapies which induce differentiation, an effect that has been seen with, and is believed to be on-target for, the proposed mechanism of action for FHD-286. The FDA has additional questions and requires further analyses before the clinical hold may be lifted, the company noted. Foghorn said that a dose escalation phase 1 trial of FHD-286 in metastatic uveal melanoma (mUM) continues per protocol and it plans to report data in H1 2023. FHTX -18.38% to $11.99 premarket Aug. 23
Seeking Alpha • Aug 09

Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M

Foghorn Therapeutics press release (NASDAQ:FHTX): Q2 GAAP EPS of -$0.66 misses by $0.07. Revenue of $4.49M (+1503.6% Y/Y).
Seeking Alpha • Jun 02

Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity

Foghorn has partnering deals with major big pharma. They have a novel technology which no one else seems to have. If they can do proof of concept, they may go up considerably.
Analysartikel • Apr 13

We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Prognoser för vinst- och omsättningstillväxt

NasdaqGM:FHTX - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/202859-57-67-347
12/31/202737-68-65-7210
12/31/202626-72-60-4910
3/31/202628-75-87-87N/A
12/31/202531-74-86-86N/A
9/30/202525-72-89-88N/A
6/30/202524-75-91-90N/A
3/31/202524-80-96-95N/A
12/31/202423-87-101-100N/A
9/30/202426-91-104-103N/A
6/30/202435-86-110-110N/A
3/31/202434-93-117-116N/A
12/31/202334-98-119-118N/A
9/30/202333-103-121-119N/A
6/30/202322-115-114-112N/A
3/31/202321-112-111-109N/A
12/31/202219-109192194N/A
9/30/202216-109233234N/A
6/30/20229-109233234N/A
3/31/20225-105243244N/A
12/31/20211-101-54-50N/A
9/30/20211-93-84-73N/A
6/30/20211-85-65-50N/A
3/31/20211-78-61-44N/A
12/31/20200-69-47-31N/A
9/30/20200-63-43-34N/A
6/30/2020N/A-58-52-49N/A
3/31/2020N/A-54-48-47N/A
12/31/2019N/A-51N/A-46N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: FHTX förväntas förbli olönsam under de kommande 3 åren.

Resultat vs marknad: FHTX förväntas förbli olönsam under de kommande 3 åren.

Höga tillväxtresultat: FHTX förväntas förbli olönsam under de kommande 3 åren.

Intäkt vs marknad: FHTX s intäkter ( 35.9% per år) förväntas växa snabbare än US marknaden ( 13% per år).

Hög tillväxtintäkter: FHTX s intäkter ( 35.9% per år) förutspås växa snabbare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: Otillräcklig data för att avgöra om FHTX s avkastning på eget kapital förväntas bli hög om tre år

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/07/13 04:50
Aktiekurs vid dagens slut2026/07/13 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Foghorn Therapeutics Inc. bevakas av 15 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Yuan ZhiB. Riley Securities, Inc.
Kalpit PatelB. Riley Securities, Inc.
Suranjit MukherjeeBTIG